Novavax price target lowered to $23 from $25 at B. Riley

B. Riley lowered the firm’s price target on Novavax to $23 from $25 and keeps a Buy rating on the shares following the Q2 report. The company’s U.S. commercial execution is “stronger than ever” and its fiscal 2024 U.S. product sales guidance remains unchanged, the analyst tells investors in a research note.